Skip to content

Betrixaban Maleate

Published: July 26, 2026Updated: August 27, 2026

Betrixaban Maleate is an oral anticoagulant that belongs to the direct factor Xa inhibitor class. It is approved for the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for acute medical illness who are at risk for thromboembolic events due to restricted mobility or other risk factors.

Quick summary

Betrixaban Maleate is an oral anticoagulant used to prevent blood clots in hospitalized patients at risk for venous thromboembolism.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 27, 2026Editorial policy

Key facts at a glance

RxNorm
1927955
Generic
Betrixaban Maleate
Class
pin-variant
Brands
—
Availability
rx
Lactation
unknown
Routes
—
Forms
—
Regions
US, EU, CN, JP
Monitoring
—

This page is for informational purposes only.

Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.

Prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for acute medical illness (such as heart failure, respiratory failure, infection, rheumatic disease, or stroke) who have risk factors for VTE including reduced mobility, advanced age, and other thrombotic risk factors.

Betrixaban is a direct factor Xa inhibitor that selectively binds to and inhibits factor Xa, a key enzyme in the coagulation cascade responsible for converting prothrombin to thrombin. By inhibiting factor Xa, it reduces thrombin generation and prevents blood clot formation.

Like all anticoagulants, betrixaban carries a risk of bleeding. It is not indicated for patients with active pathological bleeding or those requiring anticoagulation for mechanical heart valves. The medication has a longer half-life than some other DOACs, and dose adjustment may be needed in patients with severe renal impairment. Routine anticoagulant monitoring (e.g., INR) is not required.

Official drug label

WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy